8 February 2017 - The label for Eli Lilly and Company's once-weekly Trulicity (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes. 

The U.S. FDA included the changes to the approved product labeling to reflect this important information for prescribers. Trulicity is available in a prefilled pen in 0.75 and 1.5 mg doses.

"Despite best efforts to manage their A1C, many adults with type 2 diabetes may need to add to or change their treatment plan to help them reach their blood sugar goals," said Sherry Martin, M.D., vice president, Global Medical Affairs, Lilly Diabetes. "They now have the option to use Trulicity, with its powerful efficacy in a once-weekly, easy-to-use pen,* along with basal insulin for even greater control."

Trulicity is a once-weekly glucagon-like peptide-1 receptor agonist injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes. It should be used along with diet and exercise.

Read Eli Lilly press release